Company intelligence / Profile preview

Prolium Pharmaceuticals

Delaware, United States

Ownership: Private
Development stage: Other

Overview

Prolium has licensed ICP-B02/CM355, a CD20xCD3 bispecific antibody in Phase I/II trials showing preliminary efficacy in r/r NHL (FL and DLBCL) with both IV and SC formulations. Dose escalation completed for IV; SC ongoing. Expansion studies planned with combinations.[1][2][3][5][7]

Therapeutic areas: OncologyImmunology
Modalities: Bispecific monoclonal antibody
Industry: Biotech

Partnerships

InnoCare PharmaKeyMed BiosciencesBeijing Tiannuo Jiancheng Pharmaceutical Technology (JV)

Beyond the preview

Go deeper on Prolium Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prolium Pharmaceuticals.

Explore the full profile